Eradication of Malignant Carcinoma in the Breast Tissue
NCT ID: NCT02286778
Last Updated: 2017-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
60 participants
INTERVENTIONAL
2016-02-29
2017-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
NCT01281163
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT05288777
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
NCT02252887
TPI 287 in Breast Cancer Metastatic to the Brain
NCT01332630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acetogenins
Dietary Supplement: Acetogenins BID for 12 months
Acetogenins
Acetogenins BID for 12 months
Placebo
Dietary Supplement: No Acetogenins BID for 12 months
Placebo
Control
Control subjects will not receive the Acetogenins or the placebo. They will be evaluated every other month to monitor disease progress.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acetogenins
Acetogenins BID for 12 months
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Referred to the study by their treating physician
Exclusion Criteria
35 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Optimal Health Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John A Shaw, MD
Role: PRINCIPAL_INVESTIGATOR
Optimal Health Research
Steven Osguthorpe, ND
Role: PRINCIPAL_INVESTIGATOR
Optimal Health Research
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F-9892131B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.